Admission Date:  [**2101-10-3**]     Discharge Date:  [**2101-10-6**]   Service:  CCU  HISTORY OF PRESENT ILLNESS:  The patient is a 79 year-old female with a past medical history significant for hypertension and diabetes admitted to the Coronary Care Unit status post myocardial infarction and cardiac catheterization with left anterior descending coronary artery stenting times two.
The patient received aspirin and Lopresor and was started on heparin, nitroglycerin and Integrilin drips.
She was pain free upon arrival and the Coronary Care Unit team was contact[**Name (NI) **] for further management and for cardiac catheterization.
Right breast cancer status post lumpectomy and radiation therapy.
Glucotrol XL 5 mg q day.
Cranial nerves grossly intact except for bilateral auditory deficits, hearing aids in place bilaterally.
She received two cipher stents to her mid left anterior descending coronary artery with restoration of flow.
She was loaded on Plavix and Integrilin in the catheterization laboratory and continued on her daily regimen of aspirin, Plavix and statin.
She was also started on a beta blocker and ace inhibitor, which were titrated up throughout her hospital course.
She had an echocardiogram following her anterior myocardial infarction.
She was subsequently started on heparin and Coumadin.
The patient refused heparin and was then placed on Lovenox to bridge her until therapeutic on Coumadin.
Endocrine:  The patient initially placed on sliding scale insulin following her myocardial infarction for tight glucose control.
She was started on Glipizide per her home regimen.
FEN:  The patient was placed on a cardiac heart healthy diet and diabetes diet.
She was scheduled for following of her INR with plans to continue her Lovenox when therapeutic on Coumadin.
Lisinopril 5 mg po q day.
Metoprolol XL 25 mg po q day.
Aspirin 325 mg po q day.
Plavix 75 mg po q day.
Simvastatin 10 mg po q day.
Glipizide XL 5 mg po q day.
Warfarin 5 mg po q.h.s.
Lovenox 60 mg subq q 12 hours to be discontinued when therapeutic on Coumadin.
She also will be monitored by VNA for Coumadin dosing and therapeutic INR.
